Zoll Medical announced yesterday that its Zoll AED 3 defibrillator received FDA premarket approval (PMA) for use by lay rescuers.
Chelmsford, Mass.-based Zoll’s AED 3 defibrillator uses CPR technology with integrated, real-time feedback to deliver guideline-compliant CPR to improve outcomes from sudden cardiac arrest. The company touts its enhanced technology as the first in the industry to offer a full-color display with vivid rescue images, a CPR cycle timer and a color bar gauge that shows CPR compression depth.
The Zoll AED 3 system can treat adult and pediatric patients with one CPR Uni-padz electrode, a five-year, universal CPR electrode that eliminates the need to purchase separate electrode pads for adults and children. The defibrillator also includes cloud connectivity for reporting device status and access to cardiac arrest data for transmitting to medical professionals, according to a news release.
“Zoll is committed to supporting the public with all emergency preparedness needs during this COVID-19 pandemic and every day,” Zoll Resuscitation president Elijah White said in the release. “This next-generation AED enhances Zoll’s portfolio of top-of-the-line defibrillators by continuing to deliver real-time CPR feedback and providing even better support for our public access and professional customers.
“At Zoll, our mission is to provide intuitive and intelligent AEDs in every public space around the world and to enable bystanders to act quickly, appropriately, and with confidence in sudden cardiac arrest emergencies.”